US 10,376,542 B2
Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
Andrea Mahr, Tuebingen (DE); Toni Weinschenk, Aichwald (DE); Anita Weibe, Pliezhausen (DE); Colette Song, Ostfildern (DE); Oliver Schoor, Tuebingen (DE); Jens Fritsche, Dusslingen (DE); and Harpreet Singh, Houston, TX (US)
Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE)
Filed by immatics biotechnologies GmbH, Tuebingen (DE)
Filed on Aug. 25, 2017, as Appl. No. 15/686,679.
Claims priority of provisional application 62/379,864, filed on Aug. 26, 2016.
Claims priority of application No. 10 2016 115 974 (DE), filed on Aug. 26, 2016.
Prior Publication US 2018/0055883 A1, Mar. 1, 2018
Int. Cl. A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C07K 16/18 (2006.01); C12N 15/115 (2010.01)
CPC A61K 35/17 (2013.01) [A61K 39/0011 (2013.01); C07K 14/4748 (2013.01); C07K 14/70539 (2013.01); C07K 16/2833 (2013.01); C07K 16/3053 (2013.01); C12N 5/0636 (2013.01); C07K 16/18 (2013.01); C12N 15/115 (2013.01)] 19 Claims
 
1. A method of treating cancer in a HLA-A*02+ patient, wherein said cancer comprises cancer cells that overexpress SLC25A3 and present at their surface in complex with an MHC class I molecule a peptide consisting of SEQ ID NO: 61, said method comprising administering to said patient an effective amount of activated antigen-specific CD8+ cytotoxic T cells to kill the cancer cells, wherein said activated antigen-specific CD8+ cytotoxic T cells are produced by contacting in vitro CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface in complex with an MHC class 1 molecule a peptide consisting of SEQ ID NO: 61, wherein said cancer is selected from head and neck cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), renal cell carcinoma (RCC), brain cancer, gastric cancer (GC), chronic lymphatic leukemia (CLL), non-Hodgkin lymphoma (NHL), esophageal cancer, gallbladder cancer, bile duct cancer, and liver cancer (HCC).